Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1651
Glaukos
GKOS
$9.66B
| $10.3M | ﹤0.01% |
91,127
-25
| -0% | -$2.39K |
2016 Q3
37 quarters
|
|
1652
PUT
Synopsys
SNPS
$93.9B
| $10.3M | ﹤0.01% |
21,900
| – | – |
2024 Q3
5 quarters
|
|
1653
CALL
Applied Digital
APLD
$7.59B
| $10.3M | ﹤0.01% |
418,700
+347,100
| +485% | +$10M |
2025 Q3
1 quarter
|
|
1654
CALL
Ionis Pharmaceuticals
IONS
$7.24B
| $10.3M | ﹤0.01% |
129,600
-25,000
| -16% | -$1.88M |
2025 Q1
3 quarters
|
|
1655
Lamar Advertising Co
LAMR
$14.6B
| $10.2M | ﹤0.01% |
80,936
-6,819
| -8% | -$854K |
2013 Q2
50 quarters
|
|
1656
Liberty Global Class A
LBTYA
$3.04B
| $10.2M | ﹤0.01% |
916,720
-303,641
| -25% | -$3.36M |
2013 Q4
48 quarters
|
|
1657
PUT
Kohl's
KSS
$2.13B
| $10.2M | ﹤0.01% |
500,000
| – | – |
2024 Q3
5 quarters
|
|
|
WCC
1658
WESCO International
WCC
$18.6B
| $10.1M | ﹤0.01% |
41,371
-57,868
| -58% | -$14.2M |
2013 Q2
50 quarters
|
|
1659
Southern Copper
SCCO
$174B
| $10.1M | ﹤0.01% |
72,601
-5,699
| -7% | -$745K |
2013 Q2
50 quarters
|
|
1660
Cal-Maine
CALM
$3.11B
| $10.1M | ﹤0.01% |
126,861
+23,887
| +23% | +$2.1M |
2013 Q2
50 quarters
|
|
1661
Mattel
MAT
$4.36B
| $10.1M | ﹤0.01% |
507,173
-119,795
| -19% | -$2.31M |
2013 Q2
50 quarters
|
|
|
HPE.PRC
1662
Hewlett Packard Enterprise 7.625% Series C Preferred Stock
HPE.PRC
$5.31B
| $10.1M | ﹤0.01% |
150,863
-25,745
| -15% | -$1.68M |
2024 Q3
5 quarters
|
|
1663
Acadia Realty Trust
AKR
$2.56B
| $10.1M | ﹤0.01% |
489,669
+64,292
| +15% | +$1.28M |
2013 Q2
50 quarters
|
|
|
APGE
1664
DELISTED
Apogee Therapeutics
APGE
| $10.1M | ﹤0.01% |
133,193
-509,123
| -79% | -$32.1M |
2023 Q4
8 quarters
|
|
1665
PagerDuty
PD
$1.21B
| $10M | ﹤0.01% |
765,049
-110,922
| -13% | -$1.62M |
2019 Q2
26 quarters
|
|
1666
Bankunited
BKU
$3.09B
| $10M | ﹤0.01% |
224,977
+30,763
| +16% | +$1.27M |
2013 Q2
50 quarters
|
|
1667
Amer Sports
AS
$15.8B
| $10M | ﹤0.01% |
268,457
-539,856
| -67% | -$18.5M |
2024 Q1
7 quarters
|
|
1668
Oceaneering
OII
$4.41B
| $10M | ﹤0.01% |
416,792
+30,689
| +8% | +$741K |
2013 Q2
50 quarters
|
|
1669
UGI
UGI
$7.98B
| $10M | ﹤0.01% |
267,169
-59,513
| -18% | -$2.11M |
2013 Q2
50 quarters
|
|
1670
First Hawaiian
FHB
$3.07B
| $9.99M | ﹤0.01% |
394,842
+40,162
| +11% | +$998K |
2016 Q3
37 quarters
|
|
1671
Restaurant Brands International
QSR
$24.4B
| $9.99M | ﹤0.01% |
146,392
-11,294
| -7% | -$778K |
2014 Q4
44 quarters
|
|
1672
PUT
CAVA Group
CAVA
$6.36B
| $9.98M | ﹤0.01% |
170,000
-2,402,000
| -93% | -$134M |
2025 Q1
3 quarters
|
|
1673
First Financial Bankshares
FFIN
$4.61B
| $9.97M | ﹤0.01% |
333,803
-4,175
| -1% | -$132K |
2016 Q3
37 quarters
|
|
1674
Revolve Group
RVLV
$1.48B
| $9.97M | ﹤0.01% |
330,145
-46,520
| -12% | -$1.12M |
2019 Q2
26 quarters
|
|
1675
Haemonetics
HAE
$4.76B
| $9.96M | ﹤0.01% |
124,229
+4,921
| +4% | +$331K |
2013 Q2
50 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.